What is he best known for?
The fields of study he is best known for:
His main research concerns Biochemistry, Monoamine oxidase, Enzyme, Monoamine neurotransmitter and Monoamine oxidase B.
His work in Biochemistry addresses subjects such as Internal medicine, which are connected to disciplines such as Glutamine synthetase.
His Monoamine oxidase research is multidisciplinary, incorporating perspectives in Serotonin, Dopamine, Deamination and Rat liver.
Keith F. Tipton combines subjects such as Semicarbazide and Stereochemistry with his study of Enzyme.
His research in Monoamine neurotransmitter tackles topics such as Pharmacology which are related to areas like Brofaromine, MAO inhibitors, Drug discovery, Structure–activity relationship and Rasagiline.
Keith F. Tipton has researched Monoamine oxidase B in several fields, including Oxidoreductase, Multiple forms and Chaotropic agent.
His most cited work include:
- The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. (944 citations)
- The therapeutic potential of monoamine oxidase inhibitors. (877 citations)
- Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds (498 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Biochemistry, Monoamine oxidase, Enzyme, Stereochemistry and Pharmacology.
Amine oxidase, Metabolism, Glutamate dehydrogenase, Amino acid and Mitochondrion are the core of his Biochemistry study.
His Amine oxidase research incorporates themes from Oxidative deamination, Methylamine and Benzylamine.
In Monoamine oxidase, Keith F. Tipton works on issues like Monoamine neurotransmitter, which are connected to Monoamine oxidase A.
His Chromatography research extends to Enzyme, which is thematically connected.
His study in In vivo extends to Pharmacology with its themes.
He most often published in these fields:
- Biochemistry (43.31%)
- Monoamine oxidase (28.34%)
- Enzyme (27.07%)
What were the highlights of his more recent work (between 2005-2020)?
- Biochemistry (43.31%)
- Enzyme (27.07%)
- Monoamine oxidase (28.34%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Biochemistry, Enzyme, Monoamine oxidase, Amine oxidase and Pharmacology.
His Biochemistry study combines topics in areas such as Dopamine and In vivo.
Enzyme is closely attributed to Stereochemistry in his research.
His Monoamine oxidase research is multidisciplinary, relying on both Monoamine neurotransmitter and Tyramine.
Keith F. Tipton combines subjects such as Methylamine, Caffeine, Benzylamine and Antioxidant with his study of Amine oxidase.
His studies in Pharmacology integrate themes in fields like Receptor, Internal medicine, Endocrinology and Biological activity.
Between 2005 and 2020, his most popular works were:
- The therapeutic potential of monoamine oxidase inhibitors. (877 citations)
- Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project (446 citations)
- On the substrate specificities of the two forms of monoamine oxidase. (127 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Pharmacology, Biochemistry, Monoamine neurotransmitter, Monoamine oxidase and Internal medicine.
In his research on the topic of Pharmacology, Taurine and Neurotoxin is strongly related with Receptor.
His Monoamine neurotransmitter research integrates issues from Psychiatry, Structure–activity relationship, Neuroscience and Disease.
His Monoamine oxidase study introduces a deeper knowledge of Enzyme.
His Enzyme study integrates concerns from other disciplines, such as Selegiline and Dopamine.
The study incorporates disciplines such as Apoptosis, Programmed cell death and Endocrinology in addition to Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
